Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. In an interview with Fortune on July 6, Colin Murdoch, Isomorphic Labs ...

Isomorphic Labs is preparing to test AI-designed drugs in humans, marking a new phase in drug development with artificial intelligence. (Unsplash) Google DeepMind's somewhat secretive spinoff, Isomorphic Labs,

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

The oncology drug created by Isomorphic Labs using Google DeepMind’s AlphaFold 3 tool could be pivotal for cancer treatment.

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The hitherto lesser-known Google subsidiary aims to revolutionize drug development by using advanced AI to create medicines more quickly, affordably, and accurately than traditional methods.

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling breakthroughs.

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And his company is on track to put these words into practice. Isomorphic Labs,

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.